Mammographic Density as a Surrogate Marker for the Effects of Hormone Therapy on Risk of Breast Cancer
Open Access
- 1 May 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 15 (5), 961-966
- https://doi.org/10.1158/1055-9965.epi-05-0762
Abstract
Background: Some types of hormone therapy increase both risk of breast cancer and mammographic density, a risk factor for the disease, suggesting that mammographic density may be a surrogate marker for the effects of hormones on risk of breast cancer. This research was undertaken to determine whether the effect of hormone therapy on breast cancer risk is mediated by its effect on mammographic density. Methods: Individually matched cases and controls from three nested case-control studies in breast screening populations were studied. Cases had developed invasive breast cancer at least 12 months after the initial screen. Information was collected on hormone use and other risk factors at the time of the baseline mammogram, and percent density was measured by a computer-assisted method. Results: There were 1,748 postmenopausal women, of whom 426 (24.4%) were using hormones at the time of their initial screening mammogram. Current use of hormone therapy was associated with an increased risk of breast cancer (odds ratio, 1.26; 95% confidence interval, 1.0-1.6) that was little changed by adjustment for percent density in the baseline mammogram (odds ratio, 1.19; 95% confidence interval, 0.9-1.5). Percent density in the baseline mammogram was among cases greater in current users of hormones that in never-users (difference = 5.0%, P < 0.001), but the difference was smaller and nonsignificant in controls (difference = 1.6%, P = 0.3). Conclusion: Although the effects of hormone therapy on mammographic density were greater in cases than controls, we did not find evidence that these effects were causally related to risk of breast cancer. (Cancer Epidemiol Biomarkers Prev 2006;15(5):961–6)Keywords
This publication has 22 references indexed in Scilit:
- Use of menopausal hormones in the United States, 1992 through June, 2003Pharmacoepidemiology and Drug Safety, 2004
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimensClimacteric, 2001
- Effects of Estrogen and Estrogen–Progestin on Mammographic Parenchymal DensityAnnals of Internal Medicine, 1999
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997
- Quantitative Classification of Mammographic Densities and Breast Cancer Risk: Results From the Canadian National Breast Screening StudyJNCI Journal of the National Cancer Institute, 1995
- Changes in Mammographic Densities Induced by a Hormonal Contraceptive Designed to Reduce Breast Cancer RiskJNCI Journal of the National Cancer Institute, 1994
- Factors associated with mammographic patternThe British Journal of Radiology, 1985